SUN PHARMA'S HISTORY
Sun Pharmaceuticals was founded by Mr. Dilip Shanghvi in 1983 in Vapi, Gujarat with five products for the treatment of psychiatric diseases. Cardiology products were introduced in 1987 by Gastroenterology Products in 1989. Today, it is the largest chronic prescription company in India and a market leader in psychiatry, neurology, cardiology, orthopedics, ophthalmology, gastroenterology and nephrology.
The 2014 acquisition of Ranbaxy has made the company the largest pharma company in India, the largest Indian pharma company in the US, and the 5th largest specialty generic company globally.
More than 72% of Sun Pharma's sales are from markets outside India, mainly in the states. The US is the largest market, accounting for about 50% of turnover; All, formulations or finished dosage forms, account for 93% of the turnover. Manufacturing is at 26 locations including plants in the US, Canada, Brazil, Mexico and Israel. In the US, the company markets a large basket of Zenex, which has a strong pipeline awaiting approval from the US Food and Drug (FDA).
Sun Pharma was oversubscribed 55 times in 1994 on the stock market. The founding family holds a majority stake in the company. Today Sun Pharma is the second largest and most profitable pharmaceutical company in India, as well as the largest pharmaceutical company by market capitalization in the Indian markets.
The Indian pharmaceutical industry has become the third largest producer in the world in terms of volumes and is poised to become a $ 20 billion to $ 36.7 billion industry in 2015. India is still at number 14 in the world in terms of value .
In 2009, Sun Pharma's Caraco Pharmaceutical plant in Detroit closed down due to uncertain circumstances, resulting in the seizure of $ 20 million worth of drugs by the FDA for contamination issues.
In December 2016, the FDA sent Sun a warning letter about nine violations at its manufacturing plant in Halol.
Sun Pharma requested the USFDA to withdraw approval for 28 brief new drug applications (ANDAS) related to its wholly owned subsidiary Ranbaxy Laboratories.
ACQUISITIONS
Sun Pharma has complemented the growth with select acquisitions over the last two decades. In 1996, Sun bought a wholesale pharmaceutical manufacturing plant in Ahmednagar from Nol Pharmaceuticals and MJ Pharma's Dose plant in Halol, which is today approved by the US FDA. In 1997, Sun acquired Chennai-based Tamil Nadu Dad Pharmaceuticals Ltd (TDPL), primarily for their broad gynecology and oncology brands. Also in 1997, Sun Pharma made its debut in the lucrative US market with the acquisition of Caraco Pharmaceuticals, based in Detroit.
In 1998, Sun acquired several respiratory brands from Natco Pharma. Other notable acquisitions include Millet Labs and Gujarat Lyca Organics (1999), Pradeep Drug Company (2000), Phlox Pharma (2004), a plantation plant in Bryan, Ohio and ICN, Valeant Pharma and Able Labs (2005), and Chatem from Hungary. Are included. Chemistry (2008). In 2010, the company acquired a major stake in Taro Pharmaceuticals, one of the largest generic derma companies in the US, with operations in Canada and Israel. The company currently owns a ~ 69% stake in Tarot for $ 260 million.
In 2011, Sun Pharma entered into a joint venture with MSD to bring complex or differentiated generics to emerging markets (other than India).
In 2012, Sun announced the acquisition of two US companies: DUSA Pharmaceuticals, [16] a dermatology instrument company; And generic pharma company URL Pharma [17] In 2013, the company announced a R&D joint venture for ophthalmology with research company, Intraxon.
On 6 April 2014, Sun Pharma announced that it would acquire 100% of Ranbaxy Laboratories Limited, in an all-stock transaction that was valued at $ 4 billion. Daiichi Sankyo of Japan holds a 63.4% stake in Ranbaxy. Following this acquisition, Sun Pharma has become India's largest pharmaceutical company, the largest Indian Pharma company in the US and the 5th largest generic company worldwide.
In December 2014, the Competition Commission of India approved Sun Pharma's $ 3.2 billion bid to buy Ranbaxy Laboratories, but ordered firms to divest seven products to ensure that the deal does not harm competition To deliver.
In March 2015, Sun Pharma announced it had agreed to purchase GlaxoSmithKline's opiates business in Australia to strengthen its painkiller portfolio.
Sun Pharmaceuticals was founded by Mr. Dilip Shanghvi in 1983 in Vapi, Gujarat with five products for the treatment of psychiatric diseases. Cardiology products were introduced in 1987 by Gastroenterology Products in 1989. Today, it is the largest chronic prescription company in India and a market leader in psychiatry, neurology, cardiology, orthopedics, ophthalmology, gastroenterology and nephrology.
The 2014 acquisition of Ranbaxy has made the company the largest pharma company in India, the largest Indian pharma company in the US, and the 5th largest specialty generic company globally.
More than 72% of Sun Pharma's sales are from markets outside India, mainly in the states. The US is the largest market, accounting for about 50% of turnover; All, formulations or finished dosage forms, account for 93% of the turnover. Manufacturing is at 26 locations including plants in the US, Canada, Brazil, Mexico and Israel. In the US, the company markets a large basket of Zenex, which has a strong pipeline awaiting approval from the US Food and Drug (FDA).
Sun Pharma was oversubscribed 55 times in 1994 on the stock market. The founding family holds a majority stake in the company. Today Sun Pharma is the second largest and most profitable pharmaceutical company in India, as well as the largest pharmaceutical company by market capitalization in the Indian markets.
The Indian pharmaceutical industry has become the third largest producer in the world in terms of volumes and is poised to become a $ 20 billion to $ 36.7 billion industry in 2015. India is still at number 14 in the world in terms of value .
In 2009, Sun Pharma's Caraco Pharmaceutical plant in Detroit closed down due to uncertain circumstances, resulting in the seizure of $ 20 million worth of drugs by the FDA for contamination issues.
In December 2016, the FDA sent Sun a warning letter about nine violations at its manufacturing plant in Halol.
Sun Pharma requested the USFDA to withdraw approval for 28 brief new drug applications (ANDAS) related to its wholly owned subsidiary Ranbaxy Laboratories.
ACQUISITIONS
Sun Pharma has complemented the growth with select acquisitions over the last two decades. In 1996, Sun bought a wholesale pharmaceutical manufacturing plant in Ahmednagar from Nol Pharmaceuticals and MJ Pharma's Dose plant in Halol, which is today approved by the US FDA. In 1997, Sun acquired Chennai-based Tamil Nadu Dad Pharmaceuticals Ltd (TDPL), primarily for their broad gynecology and oncology brands. Also in 1997, Sun Pharma made its debut in the lucrative US market with the acquisition of Caraco Pharmaceuticals, based in Detroit.
In 1998, Sun acquired several respiratory brands from Natco Pharma. Other notable acquisitions include Millet Labs and Gujarat Lyca Organics (1999), Pradeep Drug Company (2000), Phlox Pharma (2004), a plantation plant in Bryan, Ohio and ICN, Valeant Pharma and Able Labs (2005), and Chatem from Hungary. Are included. Chemistry (2008). In 2010, the company acquired a major stake in Taro Pharmaceuticals, one of the largest generic derma companies in the US, with operations in Canada and Israel. The company currently owns a ~ 69% stake in Tarot for $ 260 million.
In 2011, Sun Pharma entered into a joint venture with MSD to bring complex or differentiated generics to emerging markets (other than India).
In 2012, Sun announced the acquisition of two US companies: DUSA Pharmaceuticals, [16] a dermatology instrument company; And generic pharma company URL Pharma [17] In 2013, the company announced a R&D joint venture for ophthalmology with research company, Intraxon.
On 6 April 2014, Sun Pharma announced that it would acquire 100% of Ranbaxy Laboratories Limited, in an all-stock transaction that was valued at $ 4 billion. Daiichi Sankyo of Japan holds a 63.4% stake in Ranbaxy. Following this acquisition, Sun Pharma has become India's largest pharmaceutical company, the largest Indian Pharma company in the US and the 5th largest generic company worldwide.
In December 2014, the Competition Commission of India approved Sun Pharma's $ 3.2 billion bid to buy Ranbaxy Laboratories, but ordered firms to divest seven products to ensure that the deal does not harm competition To deliver.
In March 2015, Sun Pharma announced it had agreed to purchase GlaxoSmithKline's opiates business in Australia to strengthen its painkiller portfolio.
SUN PHARMA Income Statement Analysis
Operating income during the year rose 9.7% on a year-on-year (YoY) basis.The company's operating profit increased by 12.5% YoY during the fiscal. Operating profit margins witnessed a fall and down at 21.7% in FY19 as against 21.2% in FY18.Depreciation charges increased by 16.9% and finance costs increased by 7.3% YoY, respectively.Other income grew by 22.3% YoY.Net profit for the year grew by 25.0% YoY.Net profit margins during the year grew from 9.4% in FY18 to 10.7% in FY19.
Comments
Post a Comment